top of page


  • AutorenbildJuergen Mairhofer

Studies confirm usefulness of enGenes Biotech’s high quality SARS CoV-2 antigens

Vienna, Austria: – Recombinant proteins specialist CDMO enGenes Biotech GmbH (enGenes) has co-authored new studies that highlight the importance of high quality antigens in monitoring SARS CoV-2 immunity and vaccination campaigns.

enGenes’ now offers three antigens that allow for differentiation of natural infection (N) vs. vaccine induced immunity (non-N, but RBD and/or Spike). The antigens are for use in different test settings and enGenes Biotech is offering its -eXpress expression platform to enable rapid scale up to commercial bioreactor scale to make testing kits available across the EU.

Which protein to target?

Most commercially available antibody tests target the nucleocapsid protein (NP), as the most common virus protein of the pandemic pathogen SARS CoV-2. NP is used in diagnostic “antibody tests” used to detect various stages of infection SARS CoV-2 coronavirus infection, including COVID-19.

However, currently available vaccinations do not stimulate an immune response against the nucleocapsid protein, which is an indicator of developed immunity due to natural infection rather than vaccination.

Different proteins need to be targeted to set up appropriate serological tests to monitor the vaccination process and the development of non-N immunity in the population.


bottom of page